global
pandem
human
immunodefici
viru
hiv
infect
grave
consequ
live
affect
infant
children
adolesc
infant
child
mortal
attribut
hiv
infect
endem
locat
set
voluntari
public
resourc
insuffici
provid
longterm
care
million
children
initi
care
rel
orphan
howev
mani
guardian
get
sick
becom
overwhelm
number
depend
provid
care
grow
number
street
children
childhead
household
often
outcom
chain
event
begin
hiv
infect
mother
partner
unit
state
perinat
transmiss
decreas
signific
extent
current
estim
indic
less
infant
born
hiv
annual
implement
recommend
univers
prenat
hiv
counsel
test
antiretrovir
arv
prophylaxi
schedul
cesarean
section
deliveri
avoid
breastfeed
rate
transmiss
event
decreas
less
unit
state
europ
howev
remain
unaccept
annual
rate
newli
diagnos
infect
among
infant
unit
state
persist
mark
racial
econom
dispar
pediatr
hiv
infect
caus
vertic
transmiss
event
common
area
antenat
hiv
seropreval
high
countri
subsaharan
africa
south
east
southeast
asia
account
pregnant
women
need
arv
prevent
vertic
transmiss
howev
global
rate
new
hiv
infect
preval
among
young
peopl
fallen
mani
countri
like
due
reduct
vertic
transmiss
rate
improv
access
effect
cart
decreas
secondari
transmiss
event
clinic
overview
perinat
infect
occur
time
rel
immunolog
immatur
inabl
control
viremia
expos
thymu
lymphoid
tissu
destruct
time
activ
thymopoiesi
lymphopoiesi
given
viru
transmit
mother
degre
human
leukocyt
antigen
class
share
mother
infant
high
viru
could
evad
protect
immun
respons
newborn
result
acceler
diseas
progress
contrast
adult
symptom
cell
deplet
develop
untreat
vertic
infect
children
within
first
year
life
addit
plasma
ribonucl
acid
rna
level
remain
elev
first
year
among
infant
decreas
less
copiesml
least
third
year
life
prolong
elev
plasma
rna
level
may
relat
kinet
viral
replic
size
pool
host
cell
permiss
viral
replic
immatur
virusspecif
immun
respons
ii
nutrit
lifestyl
infect
perinat
infect
infant
children
progress
rapidli
adult
although
world
popul
infect
compris
children
aid
death
previous
group
earli
studi
era
cart
indic
subset
children
progress
rapidli
aid
within
year
median
time
aid
remain
year
adult
opportunist
infect
oi
often
secondari
reactiv
pathogen
acquir
hiv
infect
contrast
infant
children
vertic
infect
oi
often
reflect
primari
acquisit
host
pathogen
ongo
hiv
replic
advanc
immunosuppress
exampl
young
children
activ
tuberculosi
often
present
miliari
diseas
without
effect
cart
common
oi
children
includ
seriou
bacteri
infect
pneumonia
bacteremia
common
copathogen
oi
difficult
erad
without
success
immun
reconstitut
includ
chronic
mucos
dissemin
infect
herpesvirus
name
cytomegaloviru
cmv
herp
simplex
viru
hsv
human
herp
viru
varicella
zoster
viru
vzv
primari
dissemin
reactiv
tuberculosi
major
caus
morbid
mortal
among
children
hiv
commun
infect
pathogen
endem
dissemin
diseas
mycobacterium
avium
complex
may
occur
children
hiv
advanc
immunolog
deterior
pneumocysti
jiroveci
formerli
carinii
pneumonia
pcp
common
seriou
oi
associ
high
mortal
rate
pneumonia
often
manifest
month
age
infant
vertic
acquir
hiv
infect
candidiasi
topic
oral
esophag
tracheobronchi
common
fungal
infect
children
caus
acut
chronic
central
nervou
system
cn
infect
includ
caus
cryptococcu
neoforman
toxoplasma
gondii
less
commonli
observ
oi
includ
cryptosporidiosi
system
fungal
infect
clinic
present
includ
hepatosplenomegali
failur
thrive
oral
candidiasi
recurr
diarrhea
parot
cardiomyopathi
hepat
nephropathi
development
delay
encephalopathi
lymphoid
interstiti
pneumon
recurr
bacteri
infect
specif
malign
malign
includ
nonhodgkin
bcell
burkitttyp
lymphoma
leiomyosarcoma
kaposi
sarcoma
commonli
describ
children
hiv
subsaharan
african
ethnic
unit
state
clinic
practic
number
oi
seen
children
hiv
decreas
reflect
widespread
use
administr
effect
cart
regimen
howev
oi
continu
present
symptom
hiv
infect
infant
due
lack
antenat
test
mother
adolesc
young
adult
increasingli
infect
horizont
transmiss
intestin
primari
target
organ
hiv
hiv
infect
caus
deplet
lymphocyt
gutassoci
lymphoid
tissu
includ
select
loss
subset
helper
cell
call
lymphocyt
import
gut
mucos
contain
extracellular
pathogen
salmonella
typhimurium
cell
lost
earli
retrovir
infect
replenish
time
deplet
impair
longterm
gastrointestin
gi
mucos
integr
permeabl
caus
increas
bacteri
transloc
immun
activ
intestin
mucosa
also
main
reservoir
hiv
bodi
despit
effect
virolog
suppress
cart
among
untreat
children
hiv
mani
one
intestin
disord
given
time
iron
malabsorpt
present
nearli
time
hiv
enteropathi
secondari
direct
hivmedi
injuri
indirect
immunemedi
injuri
gi
tract
mucosa
absenc
specif
opportunist
enteropathogen
perhap
reflect
select
loss
lymphocyt
hiv
enteropathi
occur
children
adolesc
stage
hiv
infect
clinic
manifest
includ
chronic
diarrhea
increas
intestin
permeabl
malabsorpt
malnutrit
histolog
chang
includ
lymphocyt
infiltr
gi
tract
mucosa
villou
atrophi
blunt
crypt
hyperplasia
direct
cytopath
effect
hiv
intestin
mucosa
support
observ
clinic
sign
symptom
improv
initi
effect
cart
associ
virolog
suppress
immun
reconstitut
cell
acut
recurr
chronic
diarrhea
associ
malabsorpt
growth
impair
frequent
occur
children
untreat
hiv
infect
advanc
immunosuppress
commonli
identifi
infect
enteropathogen
includ
bacteria
salmonella
shigella
sp
virus
includ
rotaviru
adenoviru
cmv
parasit
entamoeba
giardia
cryptosporidia
microsporidia
isospora
opportunist
fungi
children
hiv
frequent
persist
wateri
diarrhea
common
present
cryptosporidi
microsporidi
isosporidi
infect
associ
abdomin
cramp
fever
vomit
anorexia
weight
loss
poor
weight
gain
untreat
chronic
sever
diarrhea
may
caus
malnutrit
failur
thrive
sever
dehydr
combin
problem
gi
tract
diseas
caus
cmv
may
includ
esophag
gastriti
pylor
obstruct
hepat
pancreat
coliti
ascend
cholang
cholecyst
sign
symptom
may
includ
nausea
vomit
dysphagia
epigastr
pain
icteru
wateri
diarrhea
stool
may
bloodi
sigmoidoscopi
cmv
coliti
provid
nonspecif
result
show
diffus
erythema
submucos
hemorrhag
diffus
mucos
ulcer
specif
caus
diarrhea
repres
adult
subject
aid
present
tabl
data
reflect
prospect
followup
particip
swiss
hiv
cohort
studi
diarrheal
episod
evalu
standard
stool
examin
intestin
infect
diagnos
less
chronic
diarrheal
episod
site
sever
infect
vari
accord
infect
organ
oral
mucos
ulcer
secondari
infecti
agent
candida
albican
cmv
hsv
caus
inflamm
pain
swallow
eat
may
lead
reduc
oral
intak
opportunist
enteropathogen
cryptosporidium
cmv
microsporidia
may
affect
hepatobiliari
system
pancrea
addit
gi
tract
result
vomit
abdomin
pain
malabsorpt
resourcelimit
set
diseas
mycobacterium
tuberculosi
common
caus
death
subject
hiv
hiv
tuberculosi
tb
acceler
diseas
progress
mortal
associ
mark
clinic
wast
extent
wast
relat
sever
tb
largest
proport
newli
diagnos
children
hiv
mani
us
center
foreign
born
higher
risk
prior
potenti
ongo
exposur
tb
tb
almost
alway
transmit
children
adult
commonli
household
contact
infect
children
primari
infect
rather
reactiv
diseas
adult
increas
index
suspicion
tb
infect
diseas
children
hiv
particularli
context
clinic
wast
low
threshold
empir
antituberculosi
therapi
even
diagnost
investig
fail
identifi
tbcaus
organ
combin
underli
hiv
infect
nutrit
statu
particularli
proteinenergi
malnutrit
host
immun
inextric
interdepend
unit
state
prior
widespread
administr
effect
cart
predomin
effect
advanc
immunosuppress
nutrit
statu
children
hiv
wast
neg
energi
balanc
predict
morbid
mortal
precart
era
oi
major
precipit
weight
loss
necessit
prevent
prompt
diagnosi
treatment
prevent
wast
promot
weight
recoveri
growth
children
hiv
persist
normal
standard
reduc
height
weight
veloc
compar
hivexpos
uninfect
children
center
diseas
control
prevent
cdc
defin
wast
children
younger
age
year
persist
weight
loss
baselin
downward
cross
least
two
percentil
line
weightforag
chart
child
age
year
older
less
percentil
weightforheight
chart
two
consecut
measur
least
day
apart
plu
chronic
diarrhea
document
fever
least
day
whether
intermitt
constant
addit
oi
etiolog
contribut
abnorm
growth
untreat
hiv
infect
children
includ
synergist
combin
inadequ
dietari
intak
gi
malabsorpt
increas
energi
util
socioeconom
advers
preval
malnutrit
children
hiv
vari
among
center
unit
state
children
follow
pediatr
hiv
program
demonstr
evid
proteinenergi
malnutrit
turn
exacerb
immunosuppress
effect
hiv
common
pattern
wast
includ
earli
declin
weight
height
first
month
life
earli
linear
stunt
normal
weighttoheight
ratio
progress
wast
low
weight
height
also
well
recogn
commonli
associ
infecti
enteropathogen
sequenti
followup
demonstr
growth
children
untreat
hiv
infect
remain
growth
agematch
gendermatch
uninfect
control
malabsorpt
also
result
macronutri
micronutri
defici
micronutri
defici
widespread
compound
effect
hiv
infect
children
defici
manifest
condit
fatigu
reduc
learn
abil
due
anemia
iron
defici
impair
immun
defici
reflect
inadequ
nutrient
intak
consequ
excess
loss
due
oi
diarrhea
malabsorpt
previous
describ
micronutri
also
malabsorb
result
defici
includ
vitamin
folic
acid
thiamin
zinc
selenium
calcium
magnesium
fatsolubl
vitamin
evid
base
specif
effect
micronutri
supplement
children
hiv
limit
recent
cochran
review
studi
particip
made
follow
key
recommend
practic
benefit
period
vitamin
supplement
children
month
age
hiv
infect
resourcelimit
set
support
data
three
african
trial
consist
evid
benefit
supplement
uninfect
children
zinc
supplement
reduc
diarrheal
morbid
advers
effect
diseas
ii
nutrit
lifestyl
progress
singl
safeti
trial
south
african
children
children
hiv
therefor
receiv
zinc
supplement
manag
diarrhea
sever
acut
malnutrit
way
uninfect
children
condit
review
emphas
micronutri
defici
immun
dysfunct
children
hiv
would
restor
effect
suppress
hiv
replic
cart
consist
drug
target
life
cycl
hiv
specif
enzym
receptor
inhibit
replic
therebi
preserv
restor
immun
function
specif
goal
administr
cart
includ
maxim
reduct
plasma
viral
load
limit
detect
copiesml
prevent
select
drugresist
strain
mainten
good
immunolog
statu
repopul
cell
prevent
clinic
diseas
progress
oi
clinic
trial
cart
infant
children
hiv
demonstr
dramat
reduct
morbid
mortal
unit
state
sinc
widespread
implement
onward
vast
major
infant
children
expect
surviv
adulthood
five
class
arv
drug
commonli
avail
hiv
therapi
two
class
target
enzym
revers
transcriptasenonnucleosid
revers
transcriptas
inhibitor
nrti
nonnrti
third
classproteas
inhibitor
pi
target
viral
proteas
wherea
integras
inhibitor
target
correspond
enzym
addit
inhibitor
target
viral
coreceptor
permiss
target
cell
mutabl
larg
result
error
introduc
viral
genom
replic
hiv
genom
approxim
nucleotid
long
new
virion
averag
one
mutat
result
larg
pool
quasispeci
viral
variant
incap
product
infect
may
provid
adapt
benefit
exampl
develop
art
resist
virion
drugresist
viru
develop
cart
administr
poor
adher
regimen
potent
combin
ii
nutrit
lifestyl
factor
result
incomplet
virolog
suppress
addit
primari
drug
resist
may
occur
arvnaiv
infant
children
becom
infect
resist
viru
aggress
multidrug
cart
earli
infect
possibl
daili
adher
indefinit
period
advoc
fulli
suppress
viral
replic
preclud
select
emerg
resist
viral
variant
resist
test
enhanc
abil
choos
effect
initi
regimen
well
secondor
thirdlin
regimen
therapeut
strategi
continu
focu
time
initi
arv
regimen
capabl
maxim
suppress
viral
replic
order
prevent
diseas
progress
preserv
restor
quantit
qualit
immunolog
function
reduc
develop
drug
resist
difficulti
longterm
adher
cartparticularli
infant
children
variabl
drug
administr
absorpt
metabol
pretreat
matern
cart
vertic
transmiss
drugresist
viru
accept
palat
medic
refriger
syrup
formul
warm
climatesar
well
document
longterm
followup
infect
infant
children
involv
longitudin
determin
prognost
marker
includ
number
percentag
cell
viral
load
paramet
provid
use
framework
time
initi
chang
therapi
involv
frequent
venipunctur
minor
longterm
toxic
includ
lipodystrophi
syndrom
lipid
abnorm
cardiomyopathi
mitochondri
toxic
lactic
acidosi
renal
tubular
acidosi
hypersensit
reaction
cn
toxic
fortun
avail
new
drug
drug
formul
led
use
potent
regimen
reduc
shortterm
toxic
lower
pill
burden
less
frequent
medic
administr
factor
associ
better
adher
outcom
enter
parenter
supplement
appetit
stimul
improv
nutrit
statu
weight
children
untreat
hiv
infect
littl
effect
growth
veloc
height
howev
effect
virolog
suppress
cart
shown
improv
mean
weight
weight
height
muscl
mass
children
hiv
pibas
therapi
initi
maintain
median
month
effect
independ
virolog
suppress
improv
tlymphocyt
count
find
also
note
pediatr
aid
clinic
trial
group
studi
ii
nutrit
lifestyl
found
pi
therapi
improv
weight
height
zscore
annual
adjust
cell
count
age
gender
race
era
cart
follow
introduct
picontain
regimen
hivassoci
mortal
decreas
greater
signific
declin
opportunist
relat
infect
encourag
outcom
temper
side
effect
associ
arv
alter
bodi
composit
lipid
abnorm
abnorm
regul
glucos
metabol
consequ
result
increas
risk
cardiovascular
diseas
reflect
complic
inflamm
uncontrol
hiv
infect
specif
arv
drug
outlin
children
adolesc
adult
clear
syndrom
abnorm
fat
redistribut
lipodystrophi
metabol
chang
associ
administr
cart
well
describ
pattern
lipodystrophi
vari
peripher
fat
wast
lipoatrophi
face
extrem
buttock
central
fat
accumul
lipohypertrophi
abdomen
dorsocerv
spine
region
buffalo
hump
breast
condit
may
occur
alon
combin
difficult
assess
grow
child
adolesc
sinc
chang
bodi
fat
occur
normal
childhood
puberti
lipodystrophi
children
hiv
clinic
evalu
examin
selfreport
document
high
dualenergi
xray
absorptiometri
dexa
quantifi
total
trunk
limb
fat
observ
studi
children
lipodystrophi
show
decreas
total
extrem
fat
greater
trunktoextrem
fat
ratio
children
hiv
compar
uninfect
children
chang
drug
specif
associ
durat
therapi
prolong
treatment
older
age
like
result
lipodystrophi
treatment
nrti
includ
stavudin
zidovudin
azt
didanosin
ddi
associ
lower
percentag
extrem
fat
higher
percentag
trunk
fat
trunktoextrem
fat
ratio
even
adjust
wast
stunt
chang
bodi
fat
distribut
often
revers
even
switch
less
lipodystroph
arv
regimen
cohort
children
receiv
pi
regimen
higher
rate
dyslipidemia
document
higher
fast
lipid
cholesterol
triglycerid
lipodystrophi
patient
result
much
higher
waisttohip
ratio
elev
fast
insulin
level
blood
pressur
ii
nutrit
lifestyl
signific
risk
factor
cardiovascular
diseas
children
without
lipodystrophi
one
fifth
show
symptom
dyslipidemia
summari
select
arv
regimen
care
must
taken
consid
lifelong
side
effect
consequ
time
newer
less
lipodystroph
firstlin
regimen
includ
tenofovir
abacavir
ritonavirboost
pi
atazanavir
darunavir
integras
inhibitor
ad
advantag
daili
administr
avail
unit
state
regimen
includ
zidovudin
didanosin
stavudin
prescrib
less
often
children
hiv
reduc
potenti
longterm
toxic
metabol
syndrom
reflect
seri
clinic
condit
includ
elev
triglycerid
low
level
highdens
lipoprotein
hdl
cholesterol
hyperglycemia
insulin
resist
increas
bodi
fat
distribut
around
waist
high
blood
pressur
collect
increas
risk
cardiovascular
diseas
individu
hiv
preval
metabol
syndrom
higher
gener
popul
estim
although
uncontrol
hiv
absenc
cart
caus
low
hdl
cholesterol
high
triglycerid
discuss
previous
arv
also
induc
bodi
fat
redistribut
conjunct
metabol
chang
earlier
pi
includ
treatment
dose
ritonavir
without
boost
pi
nelfinavir
ritonavirboost
lopinavir
kaletra
document
increas
lipid
plasma
concentr
includ
serum
triglycerid
cholesterol
lowdens
lipoprotein
ldl
cholesterol
apolipoprotein
e
lower
hdl
virolog
control
newer
pi
integras
inhibitor
tenofovir
abacavir
may
associ
increas
serum
hdl
absenc
metabol
complic
compar
popul
norm
children
hiv
note
lowerthanexpect
bone
miner
densiti
bmd
age
gender
may
associ
delay
growth
sexual
matur
durat
hiv
infect
ethnic
diseas
sever
recent
larg
studi
american
children
adolesc
hiv
age
year
show
male
hiv
significantli
lower
bmd
tanner
stage
compar
uninfect
male
reduc
bmd
secondari
cart
administr
first
describ
dexa
scan
vertic
infect
children
sever
osteopenia
directli
relat
lipodystrophi
howev
longitudin
studi
dutch
children
show
associ
longer
cart
durat
increas
spinal
bmd
zscore
lopinavirritonavir
ii
nutrit
lifestyl
fulldos
ritonavir
tenofovir
associ
lower
bmd
children
principl
maintain
good
bone
health
youth
perinat
hiv
infect
recommend
youth
gener
adolesc
therefor
receiv
least
mg
calcium
per
day
least
iu
vitamin
per
day
diet
supplement
immun
reconstitut
inflammatori
syndrom
iri
diseasespecif
inflammatori
respons
occur
treatment
arv
initi
reiniti
chang
result
effect
virolog
suppress
immun
reconstitut
memori
cell
iri
note
occur
children
begin
art
sever
malnutrit
sever
immunosuppress
risk
factor
therefor
includ
low
nadir
high
viral
load
level
prior
initi
cart
children
adolesc
often
numer
document
oi
cart
initi
research
need
reduc
complic
optim
clinic
manag
occur
interact
hiv
infect
nutrit
great
import
two
factor
interdepend
sinc
strategi
improv
nutrit
statu
quantit
qualit
demonstr
benefici
effect
clinic
outcom
immunolog
cours
hiv
infect
cours
diseas
infant
children
hiv
numer
nutrit
need
reflect
previous
describ
impair
absorpt
decreas
oral
intak
increas
nutrient
requir
specif
advers
outcom
secondari
specif
nutrit
defici
includ
inabl
achiev
normal
weight
height
malnutrit
wast
growth
failur
stunt
neurocognit
neurodevelopment
oral
motor
delay
often
hiv
encephalopathi
earli
nutrit
intervent
therefor
essenti
must
address
simultan
administr
cart
antimicrobi
prophylaxi
neurodevelopment
intervent
collect
ii
nutrit
lifestyl
multidisciplinari
approach
effect
improv
health
outcom
overal
qualiti
life
precart
era
nutrit
caus
malnutrit
reflect
decreas
oral
intak
caus
anorexia
oral
esophag
lesion
often
opportunist
pathogen
gastroesophag
reflux
aspir
regress
nonattain
key
development
mileston
associ
oromotor
dysfunct
impair
mastic
malabsorpt
increas
energi
requir
metabol
oi
associ
neg
energi
balanc
vomit
diarrhea
gastrointestin
opportunist
enteropathogen
indirect
immunemedi
enteropathi
time
effect
cart
unavail
face
debilit
catabol
diseas
rapid
diseas
progress
infant
children
hiv
nutrit
intervent
develop
earli
pediatr
provid
target
four
key
area
prompt
manag
diarrhea
addit
isol
opportunist
enteropathogen
prescrib
appropri
antimicrobi
infecti
etiolog
manag
diarrhea
mandat
assess
hydrat
statu
rehydr
oral
intraven
rout
modif
diet
set
underli
food
intoler
lactos
fat
malabsorpt
includ
pancreat
enzym
supplement
vitamin
miner
supplement
recommend
includ
introduct
mechan
soft
diet
nutrit
supplement
manag
nausea
vomit
addit
appropri
antiemet
agent
treatment
also
includ
recommend
small
frequent
meal
liquid
intak
meal
nutrit
supplement
manag
anorexia
includ
small
nutrient
dens
food
nutrit
supplement
appetit
stimul
megestrol
acet
earli
nutrit
need
relat
uniqu
physiolog
demand
growth
develop
even
today
intervent
individu
accord
child
specif
need
relat
diseas
stage
gastrointestin
function
growth
corollari
energi
protein
requir
infant
children
hiv
yet
establish
individu
need
vari
depend
age
growth
clinic
immunolog
statu
may
increas
energi
protein
need
infant
children
hiv
slow
weight
gain
often
prescrib
highprotein
highcalori
diet
nutrit
need
met
typic
highcalori
highprotein
diet
addit
support
may
includ
oral
nutrit
supplement
overnight
feed
nasogastr
gastrostomytub
feed
commerci
formula
intact
protein
may
appropri
children
without
underli
gastrointestin
patholog
infant
children
hiv
gastrointestin
malabsorpt
receiv
semielement
formula
maxim
absorpt
element
formula
typic
prescrib
semielement
formula
toler
infant
children
hiv
unabl
consum
adequ
calori
oral
often
benefit
supplement
tube
feed
enter
tube
feed
supplement
improv
weight
gain
children
hiv
growth
failur
nasogastr
tube
feed
initi
attempt
includ
nighttim
feed
allow
child
eat
normal
throughout
day
complic
relat
nasogastr
tube
feed
includ
sinus
technic
inabl
caregiv
place
tube
administ
feed
deliveri
feed
nasogastr
tube
improv
growth
placement
perman
devic
gastrostomi
tube
consid
enter
supplement
gastrostomi
feed
improv
nutrit
number
chronic
childhood
ill
provid
adequ
energi
intak
promot
weight
gain
oral
intak
poor
miller
et
al
first
investig
effect
gastrostomi
tube
feed
weight
gain
height
bodi
composit
immun
paramet
morbid
mortal
children
hiv
weight
zscore
therapi
decreas
initi
nasogastr
feed
gastrostomi
tube
feed
significantli
improv
weight
zscore
get
back
baselin
approxim
month
initi
feed
signific
predictor
respons
gastrostomi
tube
feed
includ
higher
count
initi
lower
weightforheight
zscore
baselin
find
suggest
earli
intervent
acut
weight
loss
offer
best
chanc
improv
weight
children
hiv
children
greatest
improv
weight
gastrostomi
tube
placement
spent
less
time
hospit
greater
likelihood
surviv
compar
children
gain
weight
small
import
studi
demonstr
earli
nutrit
intervent
improv
qualiti
life
reduc
morbid
children
hiv
time
effect
cart
unavail
cart
era
complianc
medic
therapi
often
improv
reliabl
deliveri
arv
gastrostomi
tube
associ
improv
tlymphocyt
count
virolog
suppress
improv
longitudin
growth
guarino
et
al
test
hypothesi
nutrit
support
improv
intestin
immun
function
italian
children
hiv
receiv
enter
nutrit
continu
feed
receiv
total
parenter
nutrit
author
document
signific
increas
cell
count
xylos
level
bodi
weight
receiv
enter
nutrit
suggest
nutrit
intervent
may
restor
intestin
absorpt
increas
cell
number
initi
earli
cours
pediatr
hiv
infect
enter
feed
prefer
parenter
nutrit
preserv
gut
structur
parenter
nutrit
use
children
unabl
toler
gain
weight
enter
supplement
recurr
chronic
biliari
tract
pancreat
diseas
intract
diarrhea
weight
loss
megestrol
acet
oral
synthet
progesteron
use
sinc
earli
appetit
stimul
weight
gain
tend
associ
increas
bodi
fat
rather
muscl
clarick
et
al
investig
effect
megestrol
acet
treatment
weight
gain
linear
growth
children
hiv
growth
failur
averag
durat
studi
month
studi
conclud
megestrol
acet
associ
weight
gain
linear
growth
treatment
period
megestrol
acet
treatment
discontinu
poor
weight
gain
weight
loss
note
given
dramat
reduct
morbid
mortal
improv
longitudin
growth
children
hiv
unit
state
sinc
widespread
implement
effect
cart
megestrol
acet
therapeut
agent
includ
growth
hormon
anabol
steroid
oxandrolon
prescrib
rare
subject
hiv
earli
devast
effect
hiv
infect
health
infant
children
adolesc
becam
appar
requir
rapid
effect
respons
global
time
unit
state
introduct
arv
clinic
manifest
associ
hiv
infect
well
treatment
seen
increas
driven
shortand
longterm
toxic
new
formul
combin
children
hiv
manifest
reflect
metabol
chang
wast
stunt
gastrointestin
dysfunct
often
describ
new
clinic
concern
earli
relat
alter
bodi
composit
lipid
abnorm
abnorm
regul
glucos
metabol
complic
often
attribut
firstgener
nrti
pi
longterm
cardiovascular
risk
arv
subject
hiv
still
unknown
newer
pi
integras
inhibitor
becam
wide
avail
appear
fewer
metabol
advers
effect
although
ongo
surveil
arv
tenofovir
import
evalu
incid
renal
tubular
dysfunct
bmd
cours
chang
art
previou
two
decad
optim
nutrit
support
continu
cornerston
pediatr
adolesc
hiv
care
appli
principl
develop
earli
effect
support
infant
children
adolesc
hiv
principl
includ
ongo
comprehens
nutrit
assess
followup
cart
provid
effect
viral
suppress
unavail
enter
parenter
support
associ
improv
weight
bodi
composit
overal
surviv
still
key
part
care
children
adolesc
present
advanc
hiv
diseas
addit
period
vitamin
supplement
children
hiv
older
month
age
support
clinic
trial
africa
children
hiv
also
receiv
zinc
supplement
manag
diarrhea
sever
acut
malnutrit
way
uninfect
children
condit
investig
continu
studi
effect
oral
hypoglycem
agent
lipidlow
medic
lifestyl
chang
cardiovascular
risk
factor
patient
lipodystrophi
hyperlipidemia
time
obes
becom
endem
mani
commun
unit
state
unfortun
develop
longterm
health
also
implic
children
adolesc
hiv
across
unit
state
nevertheless
overal
outlook
children
hiv
improv
significantli
sinc
reflect
reduc
rate
morbid
mortal
improv
qualiti
life
perhap
measur
latter
overal
medic
burden
figur
child
medic
shown
olesk
et
al
figur
show
pill
burden
number
adolesc
patient
unit
state
last
paragraph
dr
olesk
articl
still
relev
quot
directli
compassion
comprehens
coordin
clinic
care
servic
requir
hivinfect
infant
children
adolesc
must
underestim
need
improv
longev
advanc
primari
hiv
therapi
must
let
qualiti
life
suffer
due
lack
nutrit
intervent
